Financials in USD. Standardized financial statements.
A compact view of how Aeolus Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 | FY 2008 | FY 2007 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $2.08M | $3.11M | $9.63M | $3.93M | $7.29M | $4.82M | $0 | $0 | $0 | $0 |
| Revenue Growth? | -33.3% | -67.7% | +145.2% | -46.1% | +51.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $2.88M | $3.51M | $6.97M | $3.36M | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | -$805,000 | -$398,000 | $2.67M | $568,000 | $7.29M | $4.82M | $0 | $0 | $0 | $0 |
| Gross Margin? | -38.8% | -12.8% | +27.7% | +14.5% | +100.0% | +100.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $5.35M | $5.74M | $9.71M | $3.27M | $9.66M | $8.72M | $3.64M | $2.00M | $2.52M | $3.30M |
| Operating Income? | -$3.27M | -$2.63M | -$80,000 | -$2.70M | -$2.37M | -$3.90M | -$3.64M | -$2.00M | -$2.52M | -$3.30M |
| EBITDA? | -$3.27M | -$2.63M | -$80,000 | -$2.69M | -$2.36M | $325,000 | $17.70M | -$2.15M | -$2.11M | -$3.52M |
| Income Before Tax | -$3.56M | -$2.63M | -$80,000 | -$3.21M | $1.70M | $299,000 | -$24.99M | -$1.86M | -$2.85M | -$3.08M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $22.23M | $437,000 | $51,000 | -$51,000 |
| Net Income? | -$3.56M | -$2.63M | -$80,000 | -$3.21M | $1.70M | $299,000 | -$25.87M | -$2.30M | -$2.97M | -$3.02M |
| EPS? | $-0.04 | $-0.02 | $-0.00 | $-0.03 | $0.01 | $0.01 | $-0.53 | $-0.07 | $-0.09 | $-0.10 |
| Diluted EPS? | $-0.04 | $-0.02 | $-0.00 | $-0.03 | $-0.03 | $0.00 | $-0.53 | $-0.07 | $-0.09 | $-0.10 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality